Richard Bran­son takes 23andMe pub­lic with his SPAC, as the Glax­o­SmithK­line part­ner aims to beef up drug R&D

One of the buzzi­est names in health­care and de­liv­er­ing per­son­al­ized med­i­cine di­rect­ly based on a cus­tomer’s ge­net­ics went pub­lic Thurs­day, and used a high-pro­file bil­lion­aire’s SPAC to do it.

23andMe pulled off a re­verse merg­er with Richard Bran­son’s VG Ac­qui­si­tion Corp, the com­pa­ny an­nounced Thurs­day morn­ing. The deal will de­liv­er $759 mil­lion in fund­ing via $509 mil­lion in cash and a $250 pri­vate place­ment, and val­ues the com­pa­ny at $3.5 bil­lion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN